NCT04928261 2026-01-22Evaluating 6-months of HER2-targeted Therapy in Patients With HER2 Positive Early-stage Breast Cancer That Achieve a Pathological Complete Response to Neoadjuvant Systemic TherapyOttawa Hospital Research InstitutePhase 4 Active not recruiting52 enrolled